Primary Colectomy in Patients With Stage IV Colon Cancer and Unresectable Distant Metastases Improves Overall Survival: Results of a Multicentric Study

被引:89
作者
Karoui, Mehdi [1 ,2 ]
Roudot-Thoraval, Francoise [3 ,4 ]
Mesli, Farida [1 ,2 ]
Mitry, Emmanuel [5 ,6 ]
Aparicio, Thomas [7 ,8 ]
DesGuetz, Gaetan [9 ,10 ]
Louvet, Christophe [11 ,12 ,13 ]
Landi, Bruno [14 ,15 ]
Tiret, Emmanuel [11 ,12 ,13 ]
Sobhani, Iradj [1 ,2 ]
机构
[1] UPEC, Dept GI Oncol, Creteil, France
[2] UPEC, Lab Clin Invest 4393, Creteil, France
[3] Hop Henri Mondor, AP HP, Dept Clin Res & Publ Hlth, F-94010 Creteil, France
[4] Univ Paris 12, Creteil, France
[5] Hop Ambroise Pare, AP HP, Dept GI Oncol, Boulogne, France
[6] Univ Versailles St Quentin Yvelines, Boulogne, France
[7] Univ Paris 07, Paris, France
[8] Hop Bichat Claude Bernard, AP HP, Dept GI Oncol, F-75877 Paris, France
[9] Univ Paris 08, Bobigny, France
[10] Hop Avicenne, AP HP, Dept GI Oncol, F-93009 Bobigny, France
[11] Univ Paris 06, Paris, France
[12] Hop St Antoine, AP HP, Dept GI Oncol, F-75571 Paris, France
[13] Hop St Antoine, AP HP, Dept Gen Surg, F-75571 Paris, France
[14] Univ Paris 05, Paris, France
[15] Georges Pompidou European Univ Hosp, AP HP, Dept GI Oncol, Paris, France
关键词
Stage IV colon cancer; Unresectable synchronous distant metastases; Colectomy; Chemotherapy; PRIMARY TUMOR RESECTION; COLORECTAL-CANCER; LIVER METASTASES; INITIAL TREATMENT; MANAGEMENT; CHEMOTHERAPY; SURGERY; COMBINATION; BEVACIZUMAB; CARCINOMA;
D O I
10.1097/DCR.0b013e31821cced0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND: Whether patients with stage IV colon cancer and unresectable distant metastases should be managed by primary colectomy followed by chemotherapy or immediate chemotherapy without resection of the primary tumor is still controversial. OBJECTIVE: This study aimed to evaluate predictive factors associated with survival in patients with stage IV colon cancer and unresectable distant metastases. DESIGN: This large retrospective multicentric study included 6 academic hospitals. SETTINGS: This study was conducted at 6 Paris University Hospitals (Assistance Publique-Hopitaux de Paris; Saint Antoine, Henri Mondor, Ambroise Pare, Hopital Europeen Gorges Pompidou, Bichat, and Avicenne). PATIENTS: Between 1998 and 2007, 208 patients with good performance status and stage IV colon cancer with unresectable distant metastases received chemotherapy, either as initial management or after primary tumor resection. MAIN OUTCOME MEASURES: Survival was estimated by use of the Kaplan-Meier method. Factors associated with survival were tested by means of a log-rank test. Results were expressed as median values with 95% confidence intervals. Factors independently related to survival were tested using a Cox regression model adjusted for a propensity score. RESULTS: Of the 208 patients, 85 underwent colectomy before chemotherapy, whereas 123 were treated with use of primary chemotherapy with or without biotherapy. At univariate analysis, the following factors were significantly associated with survival: primary colectomy (P = .031), secondary curative surgery (P < .001), well-differentiated primary tumor (P < .001), exclusive liver metastases (P < .027), absence of need for colonic stent (P = .009), and addition of antiangiogenic (P = .001) or anti-epidermal growth factor receptor (P = .013) drugs to chemotherapy. After Cox multivariate analysis and after adjusting for the propensity score, all of these factors, with the exception of two, colonic stent and anti-epidermal growth factor receptor drug, were found to be independently associated with overall survival. LIMITATION: This study was limited by its retrospective nature. CONCLUSIONS: In a selected population of patients with colon cancer and unresectable synchronous distant metastases, immediate colectomy followed by chemotherapy in association with targeted therapy was associated with longer overall survival. This strategy appears to be the most appropriate, especially for those with good performance status, well-differentiated tumors, and synchronous liver metastases only.
引用
收藏
页码:930 / 938
页数:9
相关论文
共 26 条
  • [1] Primary tumour resection and survival in the palliative management of metastatic colorectal cancer
    Bajwa, A.
    Blunt, N.
    Vyas, S.
    Suliman, I.
    Bridgewater, J.
    Hochhauser, D.
    Ledermann, J. A.
    O'Bichere, A.
    [J]. EJSO, 2009, 35 (02): : 164 - 167
  • [2] Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases
    Benoist, S
    Pautrat, K
    Mitry, E
    Rougier, P
    Penna, C
    Nordlinger, B
    [J]. BRITISH JOURNAL OF SURGERY, 2005, 92 (09) : 1155 - 1160
  • [3] Survival and symptomatic benefit from palliative primary tumor resection in patients with metastatic colorectal cancer: a review
    Eisenberger, Andrew
    Whelan, R. Lawrence
    Neugut, Alfred I.
    [J]. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2008, 23 (06) : 559 - 568
  • [4] Outcomes of resection and non-resection strategies in management of patients with advanced colorectal cancer
    Evans, Martyn D.
    Escofet, Xavier
    Karandikar, Sharad S.
    Stamatakis, Jeffrey D.
    [J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2009, 7
  • [5] First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases
    Galizia, Gennaro
    Lieto, Eva
    Orditura, Michele
    Castellano, Paolo
    Imperatore, Vincenzo
    Pinto, Margherita
    Zamboli, Anna
    [J]. ARCHIVES OF SURGERY, 2008, 143 (04) : 352 - 358
  • [6] Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer
    Gruenberger, Brigit
    Tamandl, Dietmar
    Schueller, Johannes
    Scheithauer, Werner
    Zielinski, Christoph
    Herbst, Friedrich
    Gruenberger, Thomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1830 - 1835
  • [7] Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
    Hapani, Sanjaykumar
    Chu, David
    Wu, Shenhong
    [J]. LANCET ONCOLOGY, 2009, 10 (06) : 559 - 568
  • [8] Joffe MM, 1999, AM J EPIDEMIOL, V150, P327
  • [9] Primary chemotherapy with or without colonic stent for management of irresectable stage IV colorectal cancer
    Karoui, M.
    Soprani, A.
    Charachon, A.
    Delbaldo, C.
    Vigano, L.
    Luciani, A.
    Cherqui, D.
    [J]. EJSO, 2010, 36 (01): : 58 - 64
  • [10] How aggressive should we be in patients with stage IV colorectal cancer?
    Kuo, LJ
    Leu, SY
    Liu, MC
    Jian, JJM
    Cheng, SH
    Chen, CM
    [J]. DISEASES OF THE COLON & RECTUM, 2003, 46 (12) : 1646 - 1652